Fox Run Management, L.L.C. Viking Therapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $553 Million
- Q2 2025
A detailed history of Fox Run Management, L.L.C. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 37,705 shares of VKTX stock, worth $1.25 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
37,705
Previous 33,431
12.78%
Holding current value
$1.25 Million
Previous $807,000
23.79%
% of portfolio
0.18%
Previous 0.13%
Shares
6 transactions
Others Institutions Holding VKTX
# of Institutions
453Shares Held
67.9MCall Options Held
7.72MPut Options Held
3.25M-
Vanguard Group Inc Valley Forge, PA10.2MShares$337 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$200 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$125 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$108 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$104 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.54B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...